À propos
Présentation
My research focuses on understanding how alternative RNA splicing and post-transcriptional regulation shape gene expression programs in human cells. I combine long-read transcriptomics with functional perturbation and molecular approaches to resolve RNA isoforms at full-length resolution and determine their contribution to hematopoietic differentiation and disease. At Institut IMAGINE, my work aims to identify pathogenic RNA signatures and develop therapeutic strategies based on transcriptome reprogramming.
Projet scientifique
My research program investigates how RNA processing shapes gene expression in hematopoiesis and how transcriptome reprogramming can drive therapeutic innovation. After several years at Institut Pasteur studying alternative splicing and gene regulation. I joined Institut Imagine to work with Pr Olivier Hermine on hematological and immune disorders. This transition allowed me to develop an integrated research program at the crossroads of RNA biology, molecular hematology, and translational medicine.
- Deep analysis of RNA-processing regulation during erythropoiesis – We seek to understand how alternative splicing and polyadenylation shape gene expression throughout human erythropoiesis, establishing a reference framework to interpret RNA-processing alterations in red-cell disorders.
- Splicing factor mutations in systemic mastocytosis and associated myelodysplastic syndromes – We examine how mutations in core splicing regulators and apoptosis-related genes (e.g., SF3B1, SRSF2, FAS) rewire signaling networks in mastocytosis, myelodysplastic syndromes, and immune dysregulation.
- Activation of fetal hemoglobin in β-hemoglobinopathies through transcriptome reprogramming – We investigate selective modulation of RNA isoform balance, particularly in BCL11A, to restore HbF expression and develop safer therapeutic strategies for β-hemoglobinopathies.
- Oncogenic transcriptome rewiring in T-cell leukemia – We explore how aberrant splicing generates cryptic isoforms and proteoforms that sustain leukemic proliferation and uncover new therapeutic vulnerabilities.
Together, we seek to better understand how RNA isoform diversity constitutes a central regulatory layer controlling hematopoietic differentiation, oncogenic transformation, and immune dysregulation. By combining mechanistic insight with functional perturbation and translational validation, we aim to transform transcriptomic complexity into actionable therapeutic strategies.
Projet scientifique
My research program investigates how RNA processing shapes gene expression in hematopoiesis and how transcriptome reprogramming can drive therapeutic innovation. After several years at Institut Pasteur studying alternative splicing and gene regulation, I joined Institut IMAGINE five years ago to work with Pr Olivier Hermine on hematological and immune disorders. This transition allowed me to develop an integrated research program at the crossroads of RNA biology, molecular hematology, and translational medicine.
- Deep analysis of RNA-processing regulation during erythropoiesis – We seek to understand how alternative splicing and polyadenylation shape gene expression throughout human erythropoiesis, establishing a reference framework to interpret RNA-processing alterations in red-cell disorders.
- RNA-processing defects in systemic mastocytosis and associated myeloid disorders – We investigate how mutations affecting splicing regulators such as SF3B1 and SRSF2, together with alterations of apoptosis-related genes such as FAS, reshape RNA isoform programs and disease phenotypes in mastocytosis, myelodysplastic syndromes, and immune dysregulation.
- Activation of fetal hemoglobin in β-hemoglobinopathies through transcriptome reprogramming – We investigate selective modulation of RNA isoform balance, particularly in BCL11A, to restore HbF expression and develop safer therapeutic strategies for β-hemoglobinopathies.
- Oncogenic transcriptome rewiring in T-cell leukemia – We explore how aberrant splicing generates cryptic isoforms and proteoforms that sustain leukemic proliferation and uncover new therapeutic vulnerabilities.
Together, we seek to better understand how RNA isoform diversity constitutes a central regulatory layer controlling hematopoietic differentiation, oncogenic transformation, and immune dysregulation. By combining mechanistic insight with functional perturbation and translational validation, we aim to transform transcriptomic complexity into actionable therapeutic strategies.
2025Journal (source)Nucleic Acids Research